SCHEMBL6421045

SCHEMBL6421045

OC[C@H]1OC(c2ncccn2)[C@@H](O)[C@@H]1O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
CDA P32320 1/20 0.50
PYGL P06737 3/20 0.46
SLC5A2 P31639 5/20 0.44
HIF1A Q16665 2/20 0.43
KDM4E B2RXH2 1/20 0.42
GMNN O75496 1/20 0.42
LMNA P02545 1/20 0.42
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
STAT6 P42226 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4666736 1.00 MAPT (0.50) MAPTCDAPYGLSLC5A2HIF1A
SCHEMBL6785146 1.00 MAPT (0.50) MAPTCDAPYGLSLC5A2HIF1A
SCHEMBL7199367 1.00 MAPT (0.50) MAPTCDAPYGLSLC5A2HIF1A
SCHEMBL8722212 1.00 MAPT (0.50) MAPTCDAPYGLSLC5A2HIF1A
SCHEMBL1525779 1.00 MAPT (0.50) MAPTCDAPYGLSLC5A2HIF1A
SCHEMBL6784675 1.00 MAPT (0.50) MAPTCDAPYGLSLC5A2HIF1A
SCHEMBL6927896 1.00 MAPT (0.50) MAPTCDAPYGLSLC5A2HIF1A
SCHEMBL28147525 0.85 HIF1A (0.45) MAPTCDAPYGLSLC5A2HIF1A
SCHEMBL2185181 0.84 CDA (0.43) MAPTCDAPYGLSLC5A2
SCHEMBL5010368 0.84 CDA (0.43) MAPTCDAPYGLSLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2851094-B2 1999-01-27 JP claimed
EP-0357571-B1 Pyrimidine nucleosides MEDIVIR AB (SE) 1996-04-03 EP claimed
EP-0357571-A2 Pyrimidine nucleosides Medivir Aktiebolag (SE) 1990-03-07 EP claimed
WO-1989012061-A1 PYRIMIDINE NUCLEOSIDES AND INTERMEDIATES MEDIVIR AB (SE) 1989-12-14 WO claimed
US-6867199-B2 Dinucleoside polyphosphate compositions and their therapeutic use INSPIRE PHARMACEUTICALS, INC. (US) 2005-03-15 US disclosed
US-20030207825-A1 Dinucleoside polyphosphate compositions and their therapeutic use Outdoor Wireless Networks LLC 2003-11-06 US disclosed
US-6555675-B2 Dinucleoside polyphosphates which facilitate secretory mechanisms, i.e. increasing the hydration of mucus secretions, stimulating the production of mucins and increasing ciliary beat frequency to facilitate clearance INSPIRE PHARMACEUTICALS, INC. 2003-04-29 US disclosed
US-20020103158-A1 Dinucleoside polyphosphate compositions and their therapeutic use as purinergic receptor agonists INSPIRE PHARMACEUTICALS, INC. 2002-08-01 US disclosed
US-6331287-B1 NONCATABOLIZING IMAGING AGENT FOR POSITRON EMISSION TOMOGRAPHY; UNIVERSITY ADVANCED BIO-IMAGING ASSOCIATES 2001-12-18 US disclosed
WO-1999044646-A1 NOVEL IMAGING AGENTS AND METHODS FOR THE PREPARATION AND USE THEREOF UNIVERSITY ADVANCED BIO-IMAGING ASSOCIATES (US) 1999-09-10 WO disclosed
US-5879661-A Imaging agents and methods for the preparation and use thereof UNIVERSITY ADVANCED BIO-IMAGING ASSOCIATES (US) 1999-03-09 US disclosed
WO-1997007829-A1 NOVEL IMAGING AGENTS AND METHODS FOR THE PREPARATION AND USE THEREOF UNIVERSITY ADVANCED BIO-IMAGING ASSOCIATES (US) 1997-03-06 WO disclosed
US-5246924-A Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1993-09-21 US disclosed
EP-0338042-A4 COMPOSITION AND METHOD FOR TREATING HEPATITIS VIRUS INFECTIONS USING 1-(2'-DEOXY-2'-FLUORO-BETA-D-ARABINOFURANOSYL)-5-ETHYLURACIL 1990-09-26 EP disclosed
EP-0357571-A2 Pyrimidine nucleosides Medivir Aktiebolag (SE) 1990-03-07 EP disclosed
WO-1989012061-A1 PYRIMIDINE NUCLEOSIDES AND INTERMEDIATES MEDIVIR AB (SE) 1989-12-14 WO disclosed
EP-0338042-A1 COMPOSITION AND METHOD FOR TREATING HEPATITIS VIRUS INFECTIONS USING 1-(2'-DEOXY-2'-FLUORO-BETA-D-ARABINOFURANOSYL)-5-ETHYLURACIL Sloan-Kettering Institute For Cancer Research (US) 1989-10-25 EP disclosed
EP-0322384-A1 Nucleosides for use in therapy Medivir Aktiebolag (SE) 1989-06-28 EP disclosed
WO-1989001776-A1 COMPOSITION AND METHOD FOR TREATING HEPATITIS VIRUS INFECTIONS USING 1-(2'-DEOXY-2'-FLUORO-BETA-D-ARABINOFURANOSYL)-5-ETHYLURACIL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1989-03-09 WO disclosed
US-3856777-A METHOD OF PRODUCING PYRIMIDINE NUCLEOSIDE DERIVATIVES AJINOMOTO KK 1974-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103158-A1 Dinucleoside polyphosphate compositions and their therapeutic use as purinergic receptor agonists P2RY1, P2RY10, P2RX3 MAPT 4776/4885CDA 304/4885PYGL 1143/4885
US-20030207825-A1 Dinucleoside polyphosphate compositions and their therapeutic use P2RY1, P2RY10, P2RY11 MAPT 4832/4885CDA 1388/4885PYGL 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.